MedTrace Logo

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

NCT02474563 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 171

Last updated 2015-06-30

No results posted yet for this study

Summary

The purpose of this study is to assess the 2-year progression-free survival rate.

Conditions

Interventions

DRUG

Bortezomib

Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.

DRUG

Melphalan

Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.

DRUG

Prednisone

Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd., Korea Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474563 on ClinicalTrials.gov